BGMA Chief Samuels Sees Boost From UK Biosimilars Pathway

Also Sets Out Aspirations For Repurposing Project And COVID Expectations

 
• By Dave Wallace
  
Mark Samuels, BGMA CEO
Mark Samuels sees the new MHRA biosimilars pathway as a “win-win” for developers and the NHS (Medicines UK)

More from Biosimilars

More from Products